Schedule 13D ownership disclosure
HedgePath Pharmaceuticals, Inc.
Security class unavailable
Event date: 2016-11-04
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 221,010,368
- Percent of class
- 59.3000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001144204-16-132227
- Form type
- SC 13D
- Filer
- Inhibitor Therapeutics, Inc.
- CIK
- CIK 1042418
- Filed
- Nov 08, 2016
- Reporting period
- Nov 04, 2016
- Description
- Schedule 13D beneficial ownership